Risks from Each Type of Intraprocedural Thrombotic Event in Primary PCI

The optimal therapeutic strategy for angiographic manifestations of thrombosis remains elusive.

Recent stenting trials using modern pharmacologic regimens have documented low rates of stent thrombosis (<1% within the first year), but intraprocedural thrombotic events (IPTE) remain clinically challenging and prognostically important. In addition, we don't know the extent to which the other IPTE components (new or worsened thrombus, abrupt closure, no-reflow or slow flow, and distal embolization) are associated with adverse events. To provide clarity, investigators conducted frame-by-frame, core-laboratory angiographic analyses for 6591 patients with ST-segment-elevation myocardial infarction (STEMI) or non–ST-segment-elevation acute coronary syndromes (NSTEACS).

The overall IPTE rate was 7.7%, higher among STEMI patients (12.2%) than NS…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Risks from Each Type of Intraprocedural Thrombotic Event in Primary PCI

Topics

Reviewing Author